Author： Maxion-Bergemann Stefanie
Publisher： Adis International
ISSN： 1170-7690
Source： PharmacoEconomics, Vol.24, Iss.1, 2006-01, pp. : 21-37
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Alosetron and irritable bowel syndrome
By Mayer Emeran A Bradesi Sylvie
Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 11, 2003-11 ,pp. :
Access to resources
Recommend
Clinical Drug Investigation, Vol. 27, Iss. 1, 2007-01 ,pp. :
Quality of Life in Irritable Bowel Syndrome
PharmacoEconomics, Vol. 19, Iss. 6, 2001-06 ,pp. :
Serotonergic modulation and irritable bowel syndrome
By Borman R.
Expert Opinion on Emerging Drugs, Vol. 6, Iss. 1, 2001-04 ,pp. :
Rifaximin for the treatment of irritable bowel syndrome
By Cremonini Filippo Lembo Anthony
Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 3, 2012-02 ,pp. :